Companies › INM

InMed Pharmaceuticals Inc (INM)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001728328 · EDGAR filings · Updated 2026-07-22

InMed Pharmaceuticals Inc (INM) has reported institutional ownership of 9.6%, with 9 institutional managers holding positions valued at $206.0K per the latest 13F reporting period. SEC filings include an active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), substantial-doubt (going concern) disclosure per the filings.

Filings this week (3)

• 2026-07-22 — 425 filed
• 2026-07-22 — 425 filed
• 2026-07-22 — Current report (8-K) filed

Every filing links to the official SEC document. Real-time filing alerts for this company are available inside the app.

Latest updates

• 2026-07-20 — 425 filed
• 2026-07-17 — Insider transaction reported (Form 4)
• 2026-07-16 — Insider transaction reported (Form 4)

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, InMed Pharmaceuticals Inc has 9 institutional holders and institutional ownership of 9.6%.

Insider activity

Insiders reported 0 transactions (0 buys, 0 sells) across 0 reporting insiders, with a net reported value of $0.

Data flags from SEC filings

Related companies

CYCLERION THERAPEUTICS INC COM (CYCN) · Aptevo Therapeutics Inc (APVO) · BIOMERICA INC (BMRA) · VIRAX BIOLABS GROUP LTD (VRAX) · IO BIOTECH INC (IOBTQ) · VYOME HOLDINGS INC (HIND)